Please try another search
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate is MIE-101 which is based on cowpea mosaic virus which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.
Name | Age | Since | Title |
---|---|---|---|
Steven W. King | 59 | 2020 | Chairman of the Board, President & CEO |
Paul J. Lytle | 56 | 2020 | Executive VP, CFO, Secretary & Director |
Carlton M. Johnson | 65 | 2001 | Director |
Robert L. Garnick | 74 | 2020 | Independent Director |
Robert A. Baffi | 69 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review